



September, 2019

We are a biotech-venture company based at Keio University in Japan. We are entrusted with the analytical testing of the metabolome (metabolites), such as amino acids, which are low molecular-weight compounds produced by plants and animals. We also provide research and development support for the R&D departments of pharmaceutical manufacturers and food companies, government offices, universities, and other organizations. Furthermore, we are engaged in the development of biomarkers that objectively evaluate specific diseases, and provide core technologies for the development of new diagnostic technology and drug discovery.

After listing on TSE Mothers in December 2013, the company has become a research and development-type bio-venture with 80 employees (23 with PhDs), as of April 1, 2019, actively investing in capital and human capital in order to make the next great strides through use of the funds obtained through the listing.

In the metabolomics industry, we are working to develop the use of metabolomics as a new pillar in new markets, such as healthcare and health industries. As part of this initiative, we opened the Department of Metabolomics Innovation at Hirosaki University School of Medicine in May 2019, and created predictive models for health and future risk of disease based on medical big data and metabolomics information, with the aim of putting them to practical use.

We have also announced Omega Scan, which is equipped with new technology for next-generation metabolomics, and is being developed in Japan and overseas as a powerful research support tool for biomarker searches. We have received highly positive feedback from customers who have used it.

In the biomarker industry, we are engaged in research and development to achieve the early commercialization of biomarkers related to mental illness and lifestyle diseases. We also plan to develop out into new business areas related to exosomes, which are considered to be biomarker treasure chests.

We will make every effort to ensure that biomarkers developed by our company contribute to preventive and personalized medicine in the future.

We will continue to develop our business through flexible investments and by providing better services, putting our customers and shareholders first, without forgetting the spirit of venture that our company grew up with in Tsuruoka. We are honored to receive the continued support from our investors.

Katsuhito Hashizume,  
Human Metabolome Technologies Group CEO

